Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy
- PMID: 30105502
- PMCID: PMC6279552
- DOI: 10.1007/s13365-018-0664-y
Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy
Abstract
HIV-associated neurocognitive disorder (HAND) persists in the combination antiretroviral therapy (cART) era and is associated with diminished quality of life. The disorder remains challenging to diagnose given the requirement for comprehensive neuropsychological testing. Blood biomarkers are needed to facilitate the diagnosis of HAND and to gauge neurological response to antiretroviral therapy. We performed a study of plasma neurofilament light chain (NFL) that included 37 HIV-infected and 54 HIV-negative adults. In the univariate mixed-effect model involving HIV-infected participants, there was a statistically significant linear relationship between composite neuropsychological score (NPT-11) and plasma NFL (slope = - 9.9, standard error = 3.0 with 95% confidence interval - 3.2 to - 16.6 and p = 0.008 when testing slope = 0). Similarly, in the multivariate mixed-effect model, higher plasma NFL was significantly associated with worse NPT-11 (slope = - 11.5, standard error = 3.3 with 95% confidence interval - 3.7 to - 19.0 and p = 0.01 when testing slope = 0). The association between NPT-11 and NFL appeared to be driven by the group of individuals off cART. In a subset of participants who had visits before and after 24 weeks on cART (n = 11), plasma NFL declined over time (median = 22.7 versus 13.4 pg/ml, p = 0.02). In contrast, plasma NFL tended to increase over time among HIV-negative participants (median 10.3 versus 12.6 pg/ml, p = 0.065, n = 54). Plasma NFL therefore shows promise as a marker of neuropsychological performance during HIV. Larger studies are needed to determine if NFL could serve as a diagnostic tool for HAND during suppressive cART.
Keywords: AIDS; Cognitive impairment; HIV; Neurofilament.
Figures




Similar articles
-
High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients.J Neurovirol. 2020 Aug;26(4):572-580. doi: 10.1007/s13365-020-00860-1. Epub 2020 Jun 10. J Neurovirol. 2020. PMID: 32524424 Free PMC article. Clinical Trial.
-
Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.J Neurovirol. 2017 Feb;23(1):106-112. doi: 10.1007/s13365-016-0466-z. Epub 2016 Jul 11. J Neurovirol. 2017. PMID: 27400930 Free PMC article.
-
Diagnostic and prognostic biomarkers for HAND.J Neurovirol. 2019 Oct;25(5):686-701. doi: 10.1007/s13365-018-0705-6. Epub 2019 Jan 3. J Neurovirol. 2019. PMID: 30607890 Free PMC article. Review.
-
Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.AIDS. 2019 Mar 15;33(4):615-625. doi: 10.1097/QAD.0000000000002121. AIDS. 2019. PMID: 30557159 Free PMC article.
-
Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.J Neurovirol. 2019 Oct;25(5):702-709. doi: 10.1007/s13365-018-0695-4. Epub 2019 Jan 4. J Neurovirol. 2019. PMID: 30610738 Free PMC article. Review.
Cited by
-
Plasma Neurofilament Light Is Not Associated with Ongoing Neuroaxonal Injury or Cognitive Decline in Perinatally HIV Infected Adolescents: A Brief Report.Viruses. 2022 Mar 24;14(4):671. doi: 10.3390/v14040671. Viruses. 2022. PMID: 35458401 Free PMC article.
-
A comprehensive data-driven analysis framework for detecting impairments in brain function networks with resting state fMRI in HIV-infected individuals on cART.J Neurovirol. 2021 Apr;27(2):239-248. doi: 10.1007/s13365-021-00943-7. Epub 2021 Mar 5. J Neurovirol. 2021. PMID: 33666883 Free PMC article.
-
Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate.PLoS One. 2019 Dec 11;14(12):e0226276. doi: 10.1371/journal.pone.0226276. eCollection 2019. PLoS One. 2019. PMID: 31826005 Free PMC article. Clinical Trial.
-
High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients.J Neurovirol. 2020 Aug;26(4):572-580. doi: 10.1007/s13365-020-00860-1. Epub 2020 Jun 10. J Neurovirol. 2020. PMID: 32524424 Free PMC article. Clinical Trial.
-
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.Alzheimers Dement. 2022 Dec;18(12):2669-2686. doi: 10.1002/alz.12756. Epub 2022 Jul 31. Alzheimers Dement. 2022. PMID: 35908251 Free PMC article. Review.
References
-
- Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, Price RW, Rosengren L, Gisslen M (2007). CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. J Neurol 254: 1026–32. - PubMed
-
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007). Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789–99. - PMC - PubMed
-
- Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK, Group H (2004). Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26: 307–19. - PubMed
-
- Cysique LA, Franklin D Jr, Abramson I, Ellis RJ, Letendre S, Collier A, Clifford D, Gelman B, McArthur J, Morgello S, Simpson D, McCutchan JA, Grant I, Heaton RK, Group C, Group H (2011). Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol 33: 505–22. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical